Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer

BACKGROUND: While the efficacy of neoadjuvant chemotherapy (NACT) in treating triple-negative breast cancer (TNBC) is generally accepted, not all patients derive benefit from this preoperative treatment. Presently, there are no validated biomarkers to predict the NACT response, and previous attempts...

Descripción completa

Detalles Bibliográficos
Autores principales: Omar, Mohamed, Nuzzo, Pier Vitale, Ravera, Francesco, Bleve, Sara, Fanelli, Giuseppe Nicolò, Zanettini, Claudio, Valencia, Itzel, Marchionni, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647131/
https://www.ncbi.nlm.nih.gov/pubmed/37964363
http://dx.doi.org/10.1186/s12967-023-04713-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647131/
https://www.ncbi.nlm.nih.gov/pubmed/37964363
http://dx.doi.org/10.1186/s12967-023-04713-3

Ejemplares similares